Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2LEBV
- Development stage
- Phase 4
- Lead developer
- Labo'Life España
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral
01
Overview
2LEBV is a micro-immunotherapy (MI) medicinal product developed by Labo'Life, designed to support the immune system in the context of Epstein-Barr virus (EBV) infection and reactivation. It is a sequential homeopathic treatment consisting of capsules containing sucrose-lactose pillules impregnated with highly diluted active ingredients, including human recombinant interleukin-1β (IL-1β), interleukin-2 (IL-2), plant-derived DNA and RNA, and specific nucleic acids (SNAs). The mechanism of action involves modulating the host's immune response; in vitro studies have shown that 2LEBV enhances phagocytosis in granulocytes and regulates the secretion of various cytokines, such as increasing IL-2, IL-4, IL-6, and TNF-α while decreasing IL-9. It is currently being evaluated in Phase 4 clinical trials for its efficacy in reducing asthenia (fatigue) and other symptoms in patients with acute or chronic EBV infections.
- Brand names
- 2LEBV
- Other names
- 2LEBV-Labo'Life
02
Targets
IL-2 (Interleukin 2)DNAIL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on 2LEBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2LEBV.